On January 29, Ge Longhui Ophthalmology-B (06622.HK) announced that Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Co., Ltd. (a wholly-owned subsidiary of the Company) and Kwangdong Pharmaceutical Co., Ltd. (“KDP”, a leading Korean company mainly engaged in pharmaceutical production and distribution) have entered into a distribution and supply agreement for BRIMOCHOL PF (2.75% carbaco/ 0.1% bromonidine tartrate) fixed-dose eye drops without preservatives.
According to the terms of the agreement, the company has the right to grant KDP exclusive distribution rights for this product in Korea to obtain drug registration on behalf of the company and to exclusively import, promote, distribute, market and sell the product. The Company will collect a non-refundable and non-deductible advance payment and may receive additional milestone payments and royalties in accordance with certain regulatory achievements and product sales.